Finzati - Logo
ZTS logo

Zoetis Inc.

ZTS • Drug Manufacturers - General
$80.04
▲ +0.45 (+0.57%)
Current price
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$33.42B
Growth
8.5%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 28.2%Positive revenue growth · 6.8%Positive free cash flow · 5.15Consistent free cash flow · 5/5Reasonable earnings multiple · 20.87
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 12:18 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$80.04
Change0.57%
Shares Out417.70M
Market Cap$33.42B
Enterprise Value$31.93B
52W Range71.47 - 160.48
Beta0.75
P/E12.77
P/S3.51
P/B10.61
P/FCF12.58
EV/Sales3.36

Investment DNA

How strong this company looks for long-term investors

81
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
82/100
Price Attractiveness
Cheap or expensive today
53/100
Why this score▼
Stable or improving margins · 28.2%Positive revenue growth · 6.8%Positive free cash flow · 5.15Consistent free cash flow · 5/5Reasonable earnings multiple · 20.87Healthy liquidity · 3.03

Analyst view

Analyst sentiment and price target

ZTS
Analyst sentiment
Based on 32 analyst votes · 2026-10-20
73/100
Bullish
Bullish
15
Hold
17
Bearish
0
Price Target
2026-08-07
Low
$85.00
Mean
$101.50
Median
$90.00
High
$160.00

Company Overview

IPO: 2/1/2013
Industry: Drug Manufacturers - General
P/B i: 10.61
Debt / Equity i: 2.85
Operating Margin: 38.00%
Net Margin: 28.23%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 2.85
Current Ratio: 3.03
Quick Ratio: 1.94
Status: Good

Warnings

  • High debt level

Insider Transactions

Recent executive and insider activity

Joseph Wetteny
Transaction: 07/10/2026
BUY
Change
—
Price
Not reported
Filing
07/14/2026
Type
BUY
Ferran Astorga Jeannette
Transaction: 07/10/2026
BUY
Change
—
Price
Not reported
Filing
07/14/2026
Type
BUY
Lagano Roxanne
Transaction: 07/10/2026
BUY
Change
—
Price
Not reported
Filing
07/14/2026
Type
BUY